{"id":"denaverine","rwe":[],"tags":[{"label":"denaverine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"spasmalgan","offLabel":[],"synonyms":["spasmalgan","denaverine hydrochloride","denaverine"],"timeline":[],"approvals":[],"brandName":"Spasmalgan","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"denaverine","explanation":"Imagine your muscle cells have special doors that let calcium in, which makes them contract. Denaverine blocks these doors, so less calcium gets in and the muscle relaxes. This helps to reduce muscle spasms and cramps.","oneSentence":"Denaverine works by blocking calcium channels in muscle cells, reducing muscle spasms.","technicalDetail":"Denaverine acts as a calcium channel blocker, specifically targeting L-type calcium channels in smooth muscle cells, which leads to a decrease in intracellular calcium levels and subsequent relaxation of the muscle."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/805","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DENAVERINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:27:42.961206","biosimilars":[],"competitors":[],"genericName":"denaverine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006845","UNII":"O14NF38MTL","CHEBI":"CHEBI:135601","INN_ID":"3029","RXNORM":"22503","UMLSCUI":"C0057383","ChEMBL_ID":"CHEMBL1614656","KEGG_DRUG":"D07787","PUBCHEM_CID":"71130","SECONDARY_CAS_RN":"3321-06-0","MESH_SUPPLEMENTAL_RECORD_UI":"C001967"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"34.0 hours","clearance":"5.7 mL/min/kg","volumeOfDistribution":"7.1 L/kg"},"publicationCount":14,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Spasmalgan, also known as Denaverine, is a small molecule drug in the denaverine class. Its exact target is unknown, but it is used to treat muscle spasms. The commercial status of Spasmalgan is unclear, and it may be patented or have generic manufacturers. Key safety considerations include its long half-life of 34.0 hours, although its bioavailability is unknown. Further research is needed to fully understand its pharmacology and clinical use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}